Pharmacological characterization of the competitive GLUK5 receptor antagonist decahydroisoquinoline LY466195 in vitro and in vivo.

Abstract

The excitatory neurotransmitter glutamate has been implicated in both migraine and persistent pain. The identification of the kainate receptor GLU(K5) in dorsal root ganglia, the dorsal horn, and trigeminal ganglia makes it a target of interest for these indications. We examined the in vitro and in vivo pharmacology of the competitive GLU(K5)-selective kainate receptor antagonist LY466195 [(3S,4aR,6S,8aR)-6-[[(2S)-2-carboxy-4,4-difluoro-1-pyrrolidinyl]-methyl]decahydro-3-isoquinolinecarboxylic acid)], the most potent GLU(K5) antagonist described to date. Comparisons were made to the competitive GLU(K5)/alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor antagonist LY293558 [(3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]-decahydroisoquinoline-3-carboxylic acid], other decahydroisoquinoline GLU(K5) receptor antagonists, and the noncompetitive AMPA receptor antagonist LY300168 [1-(4-aminophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodi-azepine]. When characterized electrophysiologically in rat dorsal root ganglion neurons, LY466195 antagonized kainate (30 microM)-induced currents with an IC50 value of 0.045 +/- 0.011 microM. In HEK293 cells transfected with GLU(K5), GLU(K2)/GLU(K5), or GLU(K5)/GLU(K6) receptors, LY466195 produced IC50 values of 0.08 +/- 0.02, 0.34 +/- 0.17, and 0.07 +/- 0.02 microM, respectively. LY466195 was efficacious in a dural plasma protein extravasation (PPE) model of migraine with an ID100 value of 100 microg/kg i.v. LY466195 was also efficacious in the c-fos migraine model, with a dose of 1 microg/kg i.v. significantly reducing the number of Fos-positive cells in the rat nucleus caudalis after electrical stimulation of the trigeminal ganglion. Furthermore, LY466195 showed no contractile activity in the rabbit saphenous vein in vitro. The diethyl ester prodrug of LY466195 was also efficacious in the same PPE and c-fos models after oral administration at doses of 10 and 100 microg/kg, respectively while having no N-methyl-D-aspartate antagonist-like behavioral effects at oral doses up to 100 mg/kg.

• Authors: Brianne Weiss, Andrew Alt, Ann Marie Ogden, Mary Gates, Donna K Dieckman, Amy Clemens-Smith, Ken H Ho, Keith Jarvie, Geihan Rizkalla, Rebecca A Wright, David O Calligaro, Darryle Schoepp, Edward L Mattiuz, Robert E Stratford, Bryan Johnson, Craig Salhoff, Mary Katofiasc, Lee A Phebus, Kathryn Schenck, Marlene Cohen, Sandra A Filla, Paul L Ornstein, Kirk W Johnson, David Bleakman
• Journal: The Journal of pharmacology and experimental therapeutics (J Pharmacol Exp Ther) Vol. 318 Issue 2 Pg. 772-81 (Aug 2006) ISSN: 0022-3565 [Print] United States
• PMID: 16690725 (Publication Type: Journal Article)

Chemical References

• 6-((2-carboxy-4,4-difluoro-1-pyrrolidinyl)methyl)decahydro-3-isoquinolinecarboxylic acid
• Blood Proteins
• Excitatory Amino Acid Antagonists
• Gluk1 kainate receptor
• Isoquinolines
• Ligands
• Proto-Oncogene Proteins c-fos
• Receptors, AMPA
• Receptors, Kainic Acid
• Benzodiazepines
• GYKI 53655
• Phencyclidine
• Calcium

Topics

• Animals
• Benzodiazepines (pharmacology)
• Binding, Competitive (drug effects)
• Blood Proteins (metabolism)
• Calcium (metabolism)
• Electrophysiology
• Excitatory Amino Acid Antagonists (pharmacology)
• Humans
• In Vitro Techniques
• Isoquinolines (pharmacology)
• Ligands
• Male
• Migraine Disorders (metabolism)
• Motor Activity (drug effects)
• Muscle Contraction (drug effects)
• Muscle, Smooth, Vascular (drug effects)
• Neurons (drug effects, metabolism)
• Phencyclidine (pharmacology)
• Proto-Oncogene Proteins c-fos (biosynthesis)
• Rabbits
• Rats
• Receptors, AMPA (antagonists & inhibitors)
• Receptors, Kainic Acid (antagonists & inhibitors)
• Saphenous Vein (cytology, drug effects)
• Transfection